AstraZeneca reports results from trial of combination therapy for prostate cancer
The CAPItello-281 trial aimed to assess the safety and efficacy of Truqap in combination with abiraterone and ADT.
AstraZeneca’s Truqap Redeems Itself with Phase III Prostate Cancer Win
Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It helps AstraZeneca position itself as a top player in the prostate cancer space,
Truqap Combo May Improve Progression for Some With Prostate Cancer
Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
AstraZeneca: Truqap Combination In Phase III Trial Shows Improvement In Advanced Prostate Cancer
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday positive high-level results from CAPItello-281 Phase III trial of
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with prostate cancer.
AstraZeneca reports positive Phase 3 results for Truqap in prostate cancer
AstraZeneca (NASDAQ:AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, or mHSPC. The study results showed that Truqap in combination with abiraterone and androgen deprivation therapy,
ABC Action News7d
ADT tells man to keep paying for security at hurricane destroyed home
A South Tampa man said ADT told him he had to keep paying for a security system at his Hurricane Helene-damaged home, even ...
Pathstone Holdings LLC Grows Holdings in ADT Inc. (NYSE:ADT)
Pathstone Holdings LLC grew its stake in ADT Inc. (NYSE:ADT – Free Report) by 3.6% during the third quarter, according to its ...
bovnews3d
ADT Inc (ADT) Stock Price Reaches $7.54: What Factors Are Influencing This Level?
On Friday, ADT Inc (ADT) stock saw a modest uptick, ending the day at $7.54 which represents no change from the prior close of of $7.54. The stock opened at $7.57 and touched a low of $7.5 during the ...
stocknews8d
3 Companies Transforming Home Automation and Security
The accelerating digital transformation is unlocking significant investment potential in the home automation and security ...
AstraZeneca’s Truqap combo demonstrated statistically significant improvement
High-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen ...
FiercePharma3d
AZ's Truqap delivers phase 3 win in prostate cancer subtype after recent breast cancer miss
High-level results from the company’s ongoing CAPltello-281 phase 3 study demonstrated that a combination of Truqap, Johnson ...
Oncology Nurse Advisor3d
Prostate Cancer BCR Risk Appears Lower With Adjuvant Apalutamide Plus ADT
Investigators explored the role of treatment intensification with androgen receptor pathway inhibitors in patients with high-risk localized prostate cancer.
Too Old to Operate1d
Impact of 11-Ketotestosterone on Progression in Patients With CRPC
The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...
9to5google6d
Review: ADT+ is the best security system for Nest users, but Google holds back the future
Security systems have been around for a long time now, but for many, they’re still overly complicated, overly expensive, ...